Core Insights - Annovis Bio, Inc. has published a new article in the journal Biomolecules, focusing on the pharmacokinetic profiles of Posiphen across different species, which consolidates years of research and provides a comprehensive comparison of the drug's behavior in various animal and human samples [1][2]. Group 1: Research Findings - The article presents findings that Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF) [2]. - Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen, with both the drug and its metabolites exhibiting rapid clearance in animal models and human subjects, although the drug remains longer in the CSF or brain [2]. - The absorption, distribution, metabolism, and excretion of Posiphen are similar in healthy volunteers and patients with Alzheimer's and Parkinson's diseases [2]. Group 2: Company Overview - Annovis Bio, Inc. is a clinical-stage drug platform company headquartered in Malvern, Pennsylvania, focusing on neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) [3]. - The company is believed to be the only one developing a drug targeting multiple neurotoxic proteins to restore axonal and synaptic activity, aiming to improve brain function and address memory loss and dementia associated with AD, as well as body and brain dysfunction related to PD [3].
Annovis Announces New Publication in a Peer-Reviewed Journal